Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Iroko Pharmaceuticals LLC. News release: New data shows that Vivlodex reduces rescue medication use in patients with osteoarthritis pain. 2016 May 12.
2. Altman R, Gibofsky A, Kivitz A, et al. A novel application of the medication event monitoring system (MEM) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain. J Pain. 2016;17(4): Suppl S70. Abstract 380.
3. S. Food and Drug Administration. Safety alert: Nizoral (ketoconazole) oral tablets: Drug safety communication—prescribing for unapproved uses, including skin and nail infections continues; linked to patient death. 2016 May 19.